Literature DB >> 28663384

Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes.

Kwan Yong Lee1, Byung-Hee Hwang2, Tae-Hoon Kim1, Chan Jun Kim3, Jin-Jin Kim2, Eun-Ho Choo3, Ik Jun Choi4, Young Choi1, Ha-Wook Park1, Yoon-Seok Koh1, Pum-Joon Kim1, Jong Min Lee3, Mi-Jeong Kim4, Doo Soo Jeon4, Jae-Hyoung Cho5, Jung Im Jung6, Ki-Bae Seung1, Kiyuk Chang7.   

Abstract

OBJECTIVE: We investigated the efficacy of coronary computed tomography angiography (CCTA) in predicting the long-term risks in asymptomatic patients with type 2 diabetes and compared it with traditional risk factors. RESEARCH DESIGN AND METHODS: We analyzed 933 patients with asymptomatic type 2 diabetes who underwent CCTA. Stenosis was considered obstructive (≥50%) in each coronary artery segment using CCTA. The extent and severity scores for coronary artery disease (CAD) were evaluated. The primary end point was major adverse cardiovascular events (MACE), including all-cause mortality, nonfatal myocardial infarction, and late coronary revascularization during a mean follow-up period of 5.5 ± 2.1 years.
RESULTS: Ninety-four patients with MACE exhibited obstructive CAD with a greater extent and higher severity scores (P < 0.001 for all). After adjusting for confounding risk factors, obstructive CAD remained an independent predictor of MACE (hazard ratio 3.11 [95% CI 2.00-4.86]; P < 0.001]). The performance of a risk prediction model based on C-statistics was significantly improved (C-index 0.788 [95% CI 0.747-0.829]; P = 0.0349) upon the addition of a finding of obstructive CAD using CCTA to traditional risk factors, including age, male, hypertension, hyperlipidemia, smoking, estimated glomerular filtration rate, and HbA1c. Both integrated discrimination improvement (IDI) and net reclassification improvement (NRI) analyses further supported this finding (IDI 0.046 [95% CI 0.020-0.072], P < 0.001, and NRI 0.55 [95% CI 0.343-0.757], P < 0.001). In contrast, the risk prediction power of the coronary artery calcium score remained unimproved (C-index 0.740, P = 0.547).
CONCLUSIONS: Based on our data, the addition of CCTA-detected obstructive CAD to models that include traditional risk factors improves the predictions of MACE in asymptomatic patients with type 2 diabetes.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28663384     DOI: 10.2337/dc16-1844

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  10 in total

1.  Diabetic Retinopathy as a Predictor of Angiographic Coronary Atherosclerosis Severity in Patients with Type 2 Diabetes Mellitus.

Authors:  Mohamed Eid; Amr Mounir; Shehab El Etriby; Ali Al Taher; Mohamed A W Ezzat
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-11       Impact factor: 3.249

Review 2.  Recent Updates on Vascular Complications in Patients with Type 2 Diabetes Mellitus.

Authors:  Chan-Hee Jung; Ji-Oh Mok
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

3.  CT-Based Leiden Score Outperforms Confirm Score in Predicting Major Adverse Cardiovascular Events for Diabetic Patients with Suspected Coronary Artery Disease.

Authors:  Zinuan Liu; Yipu Ding; Guanhua Dou; Xi Wang; Dongkai Shan; Bai He; Jing Jing; Yundai Chen; Junjie Yang
Journal:  Korean J Radiol       Date:  2022-09-05       Impact factor: 7.109

4.  Use of Coronary Computed Tomography Angiography to Screen Hospital Employees with Cardiovascular Risk Factors.

Authors:  Po-Yi Li; Ru-Yih Chen; Fu-Zong Wu; Guang-Yuan Mar; Ming-Ting Wu; Fu-Wei Wang
Journal:  Int J Environ Res Public Health       Date:  2021-05-20       Impact factor: 3.390

5.  The proper use of coronary calcium score and coronary computed tomography angiography for screening asymptomatic patients with cardiovascular risk factors.

Authors:  Shee Yen Tay; Po-Yen Chang; Wilson T Lao; Ying Chin Lin; Yi-Han Chung; Wing P Chan
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

6.  Practical cardiovascular risk calculator for asymptomatic patients with type 2 diabetes mellitus: PRECISE-DM risk score.

Authors:  Young Choi; Yeoree Yang; Byung-Hee Hwang; Eun Young Lee; Kun Ho Yoon; Kiyuk Chang; Farouc A Jaffer; Jae-Hyoung Cho
Journal:  Clin Cardiol       Date:  2020-07-13       Impact factor: 2.882

7.  Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study.

Authors:  Rafael Simó; Ignacio Ferreira; Jordi Bañeras; Cristina Hernández; José Rodríguez-Palomares; Filipa Valente; Laura Gutierrez; Teresa González-Alujas; Santiago Aguadé-Bruix; Joan Montaner; Daniel Seron; Joan Genescà; Anna Boixadera; José García-Arumí; Alejandra Planas; Olga Simó-Servat; David García-Dorado
Journal:  BMJ Open Diabetes Res Care       Date:  2019-12-29

8.  Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea.

Authors:  Seung-Hwan Lee; Kyungdo Han; Hun-Sung Kim; Jae-Hyoung Cho; Kun-Ho Yoon; Mee Kyoung Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2020-09-22

9.  Hemoglobin A1C Levels are Independently Associated with the Risk of Coronary Atherosclerotic Plaques in Patients without Diabetes: A Cross-Sectional Study.

Authors:  Wei-Ting Wang; Pai-Feng Hsu; Chung-Chi Lin; Yuan-Jen Wang; Yaw-Zon Ding; Teh-Ling Liou; Ying-Wen Wang; Shao-Sung Huang; Tse-Min Lu; Po-Hsun Huang; Jaw-Wen Chen; Wan-Leong Chan; Shing-Jong Lin; Hsin-Bang Leu
Journal:  J Atheroscler Thromb       Date:  2019-12-27       Impact factor: 4.928

10.  Prognostic Value of Atherosclerotic Extent in Diabetic Patients with Nonobstructive Coronary Artery Disease.

Authors:  Yipu Ding; Zinuan Liu; Guanhua Dou; Xia Yang; Xi Wang; Dongkai Shan; Bai He; Jing Jing; Yundai Chen; Junjie Yang
Journal:  J Diabetes Res       Date:  2021-06-09       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.